← Back to Clinical Trials
Recruiting NCT06259162
NCT06259162 LAG3 Expression in Triple Negative Breast Cancer
◆ AI Clinical Summary
Plain-language summary for patients
| NCT ID | NCT06259162 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Samsung Medical Center |
| Condition | Triple Negative Breast Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 128 participants |
| Start Date | 2022-11-18 |
| Primary Completion | 2025-07-01 |
Trial Parameters
Condition Triple Negative Breast Cancer
Sponsor Samsung Medical Center
Study Type INTERVENTIONAL
Phase N/A
Enrollment 128
Sex FEMALE
Min Age N/A
Max Age N/A
Start Date 2022-11-18
Completion 2025-07-01
All Conditions
Interventions
LAG-3 expression / immune checkpoint protein expression
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
This study is the experimental study for relationship between LAG-3 expression / immue checkpoint protein expression and neoadjuvant chemotherapy plus immune checkpoint inhibitor in triple negative breast cancer.
Eligibility Criteria
Inclusion Criteria: * Planned neoadjuvant chemotherapy * Triple negative breast cancer Exclusion Criteria: * HER2-positive breast cancer * Hormone receptor positive breast cancer
Related Trials
NCT06471205
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recur
View Trial →
NCT06367088
Cadonilimab Combined With Chemotherapy as First or Second Line Treatment in Recurrent or Metastatic
View Trial →
NCT07525869
An Open-label Prospective Study to Evaluate the Efficacy and Safety of Pegfilgrastim in Triple-Negat
View Trial →
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology